Aquestive Therapeutics (AQST) closed at $3.57 on November 12, 2026, down 0.3% from the previous close, on volume of 2,521,093 shares (30-day average 2,279,652).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Call Spread | 21-May-274 : 6 C | 400 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Analysts Are Bullish on Top Healthcare Stocks: Aquestive Therapeutics (AQST), Kardigan, Inc. (KARD)
TipRanks (Mon, 9-Nov 7:50 AM ET)
Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Tue, 3-Nov 4:01 PM ET)
Globe Newswire (Tue, 27-Oct 7:00 AM ET)
Globe Newswire (Thu, 15-Oct 7:00 AM ET)
Globe Newswire (Wed, 14-Oct 6:50 AM ET)
PRNewswire (Wed, 7-Oct 9:31 AM ET)
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Globe Newswire (Tue, 29-Sep 7:00 AM ET)
Globe Newswire (Thu, 17-Sep 7:00 AM ET)
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Aquestive Therapeutics trades on the NASDAQ stock market under the symbol AQST.
As of November 13, 2026, AQST stock price climbed to $3.68 with 624,019 million shares trading.
AQST has a beta of 1.09, meaning it tends to be more sensitive to market movements. AQST has a correlation of 0.03 to the broad based SPY ETF.
AQST has a market cap of $461.66 million. This is considered a Small Cap stock.
Last quarter Aquestive Therapeutics reported $8 million in Revenue and -$.13 earnings per share. This fell short of revenue expectation by $-3 million and met earnings estimates .
In the last 3 years, AQST traded as high as $7.55 and as low as $1.55.
The top ETF exchange traded funds that AQST belongs to (by Net Assets): VTI, IWM, VXF, XPH, VTWO.
AQST has underperformed the market in the last year with a price return of -34.1% while the SPY ETF gained +10.8%. AQST has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.0% and -8.9%, respectively, while the SPY returned -2.7% and -2.6%, respectively.
AQST support price is $3.43 and resistance is $3.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AQST shares will trade within this expected range on the day.
